• Cisplatin: Benchmark DNA Crosslinking Agent for Cancer Re...

  2026-03-16

  Cisplatin (CDDP) is the gold-standard DNA crosslinking agent that enables rigorous interrogation of apoptosis, tumor growth inhibition, and chemotherapy resistance in cancer models. This article spotlights advanced workflows, troubleshooting strategies, and data-driven insights—empowering cancer researchers to maximize the translational impact of APExBIO’s Cisplatin.

• Epigenetic Frontiers in Acute Myeloid Leukemia: Strategic...

  2026-03-16

  This thought-leadership article explores the mechanistic and translational promise of SP2509, a potent, selective LSD1 antagonist, in acute myeloid leukemia (AML) research. Bridging mechanistic insight with strategic guidance, it frames SP2509’s disruption of the LSD1-CoREST complex as a decisive intervention in cancer epigenetics, details evidence from preclinical models, situates SP2509 within the evolving landscape of epigenetic modulators, and envisions future paths for combinatorial therapies. The discussion integrates findings from leading studies, including combinatorial targeting of chromatin regulators, and offers actionable perspectives for translational researchers.

• JNJ-26854165 (Serdemetan): Advancing p53 Pathway Targetin...

  2026-03-15

  JNJ-26854165 (Serdemetan) stands out as a next-generation HDM2 ubiquitin ligase antagonist, enabling precise p53 activation and robust anti-proliferative responses in diverse tumor models. Leveraging APExBIO’s reliable formulation, researchers can optimize radiosensitization, apoptosis induction, and advanced cancer assay reproducibility—all backed by rigorous workflow guidance and troubleshooting insights.

• ML385: Advanced NRF2 Inhibition for Cancer and Ferroptosi...

  2026-03-14

  Explore how the selective NRF2 inhibitor ML385 enables breakthrough research in oxidative stress, cancer therapeutic resistance, and ferroptosis. This article offers a unique, mechanistic perspective on ML385's applications, including in vivo and combination therapy strategies.

• Eltanexor (KPT-8602): Advanced Insights into Nuclear Expo...

  2026-03-13

  Explore the mechanistic depth of Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, in cancer research. This article uniquely dissects its impact on nuclear export, Wnt/β-catenin signaling, and translational applications in both hematological and colorectal malignancies.

• Myriocin (SKU B6064): Optimizing Sphingolipid Metabolism ...

  2026-03-13

  This article addresses common experimental challenges in cell viability, proliferation, and cytotoxicity assays by exploring validated, scenario-based applications of Myriocin (SKU B6064). Drawing on peer-reviewed data and workflow considerations, it demonstrates how APExBIO's Myriocin enhances reproducibility and mechanistic insight for biomedical researchers. Practical recommendations and comparative analyses guide better assay outcomes and resource selection.

• VE-822 ATR Inhibitor: Precision DNA Damage Response in PD...

  2026-03-12

  VE-822 ATR inhibitor stands apart with its unmatched selectivity and potency, enabling precise disruption of DNA damage response pathways in cancer research. Applied in both traditional and iPSC-based workflows, this reagent empowers researchers to sensitize pancreatic cancer cells to chemoradiotherapy while offering robust troubleshooting support for reproducible, high-impact experiments.

• Brefeldin A (BFA): ATPase and Vesicle Transport Inhibitor...

  2026-03-12

  Brefeldin A (BFA) is a potent ATPase inhibitor that blocks ER-to-Golgi protein trafficking, widely used to induce ER stress and study apoptosis in cancer research. APExBIO’s BFA (SKU B1400) offers reproducible performance in assays requiring vesicle transport inhibition and ER stress pathway interrogation. The product’s mechanism and benchmarks are supported by peer-reviewed data and standardized protocols.

• Mitomycin C: Antitumor Antibiotic and DNA Synthesis Inhib...

  2026-03-11

  Mitomycin C is a potent antitumor antibiotic and DNA synthesis inhibitor widely used in apoptosis signaling and cancer research. Its mechanism relies on DNA cross-linking and replication inhibition, with proven effectiveness in both in vitro and in vivo models. This article details its biological rationale, benchmarks, and best practices for experimental workflows.

• AZ505: Unraveling SMYD2 Inhibition in Epigenetic Regulati...

  2026-03-11

  Discover how AZ505, a potent and selective SMYD2 inhibitor, is transforming epigenetic regulation research with groundbreaking insights into histone methylation and fibrotic disease mechanisms. This article offers a unique, in-depth analysis of substrate-competitive SMYD2 inhibition beyond cancer biology.

• RITA (NSC 652287): MDM2-p53 Interaction Inhibitor for Adv...

  2026-03-10

  RITA (NSC 652287) is revolutionizing p53 pathway research as a selective MDM2-p53 interaction inhibitor, enabling ultra-sensitive apoptosis assays and tumor xenograft models. Discover data-driven workflows, troubleshooting strategies, and unique applications that set RITA apart for renal carcinoma research and cancer biology innovation.

• Nutlin-3a: Potent MDM2 Inhibitor for p53 Pathway Activati...

  2026-03-10

  Nutlin-3a is a benchmark small-molecule MDM2 inhibitor that activates the p53 pathway, induces cell cycle arrest, and promotes apoptosis in cancer models. As shown by robust in vitro and in vivo studies, Nutlin-3a’s molecular mechanism involves blockade of the MDM2-p53 interaction, leading to p53 stabilization and anti-tumor effects. This article provides a machine-readable, citation-rich overview of Nutlin-3a’s evidence base and laboratory integration.

• Ferrostatin-1: Decoding TEAD-Linked Ferroptosis in Diseas...

  2026-03-09

  Explore how Ferrostatin-1, a selective ferroptosis inhibitor, uniquely intersects with TEAD signaling and lipid peroxidation pathways in cancer and neurodegenerative research. Gain advanced insights for designing robust ferroptosis assays and translational studies.

• ML385 (SKU B8300): Reliable NRF2 Inhibition for Advanced ...

  2026-03-09

  This article delivers an evidence-based, scenario-driven exploration of ML385 (SKU B8300), a selective NRF2 inhibitor, for biomedical researchers tackling cancer resistance, oxidative stress, and neurodegeneration. Drawing on validated best practices and published data, it demonstrates how ML385 supports experimental reproducibility and robust pathway analysis in both cell-based and in vivo models.

• Myriocin: A Multifaceted SPT Inhibitor Transforming Cance...

  2026-03-08

  Explore how Myriocin, a potent serine palmitoyltransferase inhibitor, drives advanced sphingolipid metabolism research and uncovers new therapeutic strategies for cancer and metabolic disorders. This in-depth analysis highlights unique mitochondrial and cell cycle regulation mechanisms, providing insights not found in other reviews.

16676 records 1/1112 page Next 12345 下5页 Last page